Undergoing research aims at identifying selective compounds able to open/activate CLC-7 or to slow the accelerated activation of CLC-7 observed in several patients, and siRNA against specific CLC-7 mutants can be feasible in some therapeutically neglected form of osteopetrosis (Capulli et al., 2015). The gene discussed is CLCN7; the disease is osteopetrosis.